Skip to main content
NIH funding notice RFA-CA-20-020

Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trials Not Allowed)

Closed on September 29, 2020.

Posted
December 4, 2019
Close date
September 29, 2020
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

Competing awards, new and renewals, since FY2014, under this notice and the notices it replaced.

Past awards
1
1 new
First-year cost
$373,962
Institutions
1
1 contact PI

Awards by fiscal year

Fiscal years 2014 to 2026.

Most frequent institutions

  1. UNIVERSITY OF CALIFORNIA-IRVINE1

Most frequent study sections

  1. Special Emphasis Panel (ZCA1 SRB-E (J1))1
1 award under RFA-CA-20-020 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
FY2021Microfluidic tumor tissue processing platform for single cell diagnostics1R33CA251006-01A1Haun, Jered BrackstonUNIVERSITY OF CALIFORNIA-IRVINE, CAFirst-year cost $373,962Study section ZCA1
Newest fiscal year first, then first-year cost.

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-12-0.3.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for departments

Open NIH notices that fit your faculty

See which open NIH funding notices fit each faculty member's CV, why each fits, and who won before.